Bumped- cause of new info link concerning 'Flare issues' found in about
1/3 of patients using this, via scans this was found:
The results of the study showed the following:
•22/33 patients (67 percent) had a PSA decline of ≥ 50 percent at week 12.
•26/33 patients (76 percent) had a PSA decline of ≥ 50 percent overall.
•Undetectable PSA levels (≤ 0.1 ng/ml) were documented in two patients.
•Average (median) time on therapy was 63 weeks.
•Average (median) time to PSA progression was 16.3 months.
•23/33 patients (70 percent) were evaluable for bone scan flare.
◦12/23 evaluable patients (52 percent) showed disease progression on bone scan, as indicated in radiologists’ reports.
◦11/12 patients showing signs of progression subsequently showed improvement or stability.•As defined above, bone scan flare was observed in 11/23 evaluable patients (48 percent) or 11/33 enrolled patients (patients).
•Adverse events to abiraterone therapy were typically grade 1/2 and were consistent with adverse events in prior published reportshttp://prostatecancerinfolink.net/
(the source of this claim and quoted studieds above)
Not against choices for patients, do advise people to know all they can and look at everything, without being rushed into any decisions on anything.
Post Edited (zufus) : 6/24/2011 10:34:28 AM (GMT-6)